MedPath

Pilot Study to Evaluate Efficacy of Botanical Extracts as Protein Amplifier for Skeletal Muscle Strength & Growth.

Not Applicable
Completed
Conditions
Muscle Strength
Interventions
Other: Placebo with Exercise
Other: IP I
Other: IP III
Other: IP II
Other: Placebo without Exercise
Registration Number
NCT04949789
Lead Sponsor
Vedic Lifesciences Pvt. Ltd.
Brief Summary

Sponsor proposes ingredients that when added to daily whey supplementation, can lead to increased muscle strength, improves sleep quality and reduction in fatigue level.

Detailed Description

The present study is a randomized, blinded, placebo-controlled, pilot study. Approximately 40 males aged between ≥ 20 and ≤ 35 years, will be screened. Each trial arm will have at least 5 completed after accounting for dropout/withdrawal rate of 20%. The treatment duration for all the study participants will be 28 to 56 days (Day 56 is only applicable for participants with less than 10% increase in weight leg pressed for 1 RM on Day 28. All participants in arm 1 of study will have their end of study visit on Day 28).Sponsor proposes ingredients that when added to daily whey supplementation, can lead to increased muscle strength, improves sleep quality and reduction in fatigue level.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
28
Inclusion Criteria
  1. Males aged 20 - 35 years with active lifestyle moderate physical activity level as per International Physical Activity Questionnaire.
  2. Recreationally active but not participating in resistance type training on regular basis.
  3. Body mass index (BMI) 22 - 29.9 kg/ m2
  4. Participants with an Insomnia Severity Index score ≥7 and ≤14
  5. Ready to refrain from caffeinated products and intense strength/ endurance exercise for 24 hrs. prior to the exercise lab visit.
  6. Fasting Glucose ≤ 110 mg/ dl
  7. Systolic Blood Pressure ≤ 129 mm Hg and Diastolic Blood Pressure ≤ 89 mm Hg
  8. TSH (thyroid stimulating hormone) ≥0.4 and ≤ 4.9 mIU/L
Exclusion Criteria
  1. Engaged in structured weight training during the previous 12 months prior to screening.
  2. Presence of chronic disease.
  3. Changes in body weight more than 4.5 kg (10 pounds) in the past three months.
  4. Participants with uncontrolled hypertension.
  5. Participants who are diagnosed with Type II Diabetes Mellitus.
  6. History or presence of clinically significant renal, hepatic, endocrine, biliary, gastrointestinal, pancreatic, or neurologic disorders.
  7. Allergy to whey or herbal ingredients.
  8. Participants who have any other disease or condition, or are using any medication, that in the judgment of the investigator would put them at unacceptable risk for participation in the study or may interfere with evaluations in the study or noncompliance with treatment or visits.
  9. Participants who have been part of a clinical trial within 90 days prior to the screening.
  10. Participants who have used whey or other supplemental proteins anytime in last 3 months

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placebo with ExercisePlacebo with Exercise2 Capsules to be taken 30 minutes before breakfast. * Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner. * On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption.
IP IIP I2 Capsules to be taken 30 minutes before breakfast. * Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner. * On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption.
IP IIIIP III2 Capsules to be taken 30 minutes before breakfast. * Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner. * On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption.
IP IIIP II2 Capsules to be taken 30 minutes before breakfast. * Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner. * On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption.
Placebo without ExercisePlacebo without Exercise2 Capsules to be taken 30 minutes before breakfast. * Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner. * On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption.
Primary Outcome Measures
NameTimeMethod
1-Repetition MaximumDay 0 to Day 28 and /or day56

The final weight lifted successfully for atleast 1 repetition but could not complete 3 repetition will be recorded as 1- RM.

Change in muscle strength as indicated by increase in 1Repetition Maximum leg press weight

Secondary Outcome Measures
NameTimeMethod
Visual Analogue Scale for FatigueDay 0 to Day 28 and /or day56

Reduction in fatigue level as assessed by the 11-point Visual Analogue scale for Fatigue

Body fat composition: Lean Muscle Mass by Dual-energy X-ray absorptiometryDay 0 to Day 28 and /or day56

Increase in lean muscle mass by DXA

Mid-thigh GirthDay 0 to Day 28 and /or day56

Increase in mid-thigh muscle-girth (prior to exercise) at midpoint between inguinal fold and superior border of patella.

Digestive diaryDay 0 to Day 28 and /or day56

Participants will be asked to fill out a paper/online digestive diary to monitor any significant changes that might occur to the digestive system due to the consumption of WPI and the IP.

there should be No significant effect on digestive system as per participant digestive diary.

Quality of Sleep: Modified Insomnia Severity IndexDay 0 to Day 28 and /or day56

Improvement in sleep quality as assessed by the modified Insomnia Severity Index

Trial Locations

Locations (1)

Vedic Lifesciences

🇮🇳

Mumbai, Maharashtra, India

© Copyright 2025. All Rights Reserved by MedPath